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Objectives African Americans have a high incidence of heart failure (HF). Limited retrospective observational subgroup anal-
yses of patients with left ventricular systolic dysfunction (LVSD) suggest marginal benefit of angiotensin-
converting enzyme inhibitors in the prevention of HF hospitalizations or total mortality in African Americans.
Background Very few data exist concerning the effectiveness of angiotensin receptor blockers in this population.
Methods Baseline characteristics, treatments, and outcomes of patients from the U.S. (3,390 white and 340 African-
American patients) in the VALIANT (VALsartan In Acute myocardial iNfarcTion) trial were compared. This trial
included patients with an acute myocardial infarction (MI) after initial stabilization and documented LVSD
and/or HF. Patients were randomly assigned to receive treatment with valsartan, captopril, or the combination;
follow-up continued for up to 3 years (median 24.7 months).
Results African Americans had more coronary risk factors, more markers of poor outcome after MI, and were less likely
to be revascularized when compared with white patients. After adjusting for treatment assignment, baseline
characteristics, and post-infarction parameters, no difference was found in the 3-year rate of all-cause mortality,
cardiovascular mortality, rehospitalization for HF, recurrent MI, or stroke between the 2 groups.
Conclusions African Americans sustaining an acute MI with LVSD and/or HF had similar clinical outcomes compared with
white Americans. Valsartan, captopril, or the combination had comparable effects on cardiovascular morbidity
and mortality in African Americans and white Americans. (J Am Coll Cardiol 2008;51:1865–71) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.050s
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teart failure (HF) and/or left ventricular systolic dysfunc-
ion (LVSD) frequently complicate acute myocardial infarc-
ion (MI), and significantly worsen the prognosis of patients
ith coronary heart disease (CHD) (1). African Americans
ith CHD have the highest mortality rates and have shown
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007, accepted December 11, 2007.lower declines in CHD mortality relative to white Amer-
cans (2). African Americans also have disproportionately
igher rates of HF, and the diagnosis carries higher mor-
idity (3–5). Compared with white patients, overall mortal-
ty among African Americans with HF is higher. Because
he incidence of MI in African Americans is thought to be
ower than in white patients, a higher incidence of hyper-
ension is often cited as the dominant cause of HF.
See page 1872
Several large randomized controlled trials have shown
hat angiotensin-converting enzyme (ACE) inhibitors re-
uce mortality and other adverse outcomes in the treatment
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Racial Analysis of Patients With MI, HF, and/or LVSD May 13, 2008:1865–71of acute MI with LVSD (6–12).
The efficacy of neurohormonal
antagonists, specifically ACE in-
hibitors, in African-American
patients has been questioned
given several clinical trials show-
ing a diminished effect on blood
pressure and prevention of HF in
African-American patients treated
with ACE inhibitors compared
with white Americans (13). Addi-
tionally, retrospective analyses
have suggested that ACE inhibi-
tors are less effective in African
Americans with chronic HF based
on higher hospitalization rates on
treatment for African Americans
compared with white Americans
(4,14). Prior studies have not ex-
amined the effect of angiotensin
eceptor blockers (ARBs) or the combination of ACE inhib-
tors and ARBs in African-American HF patients relative to
imilarly treated white Americans. The VALIANT (VALsar-
an In Acute myocardial iNfarcTion trial) studied 14,703
atients and compared the effectiveness of an ACE inhibitor,
RB, and their combination among patients with MI com-
licated by LVSD, HF, or both (12). Acute MI was diagnosed
y a typical clinical presentation and/or electrocardiographic
hanges and abnormal cardiac markers. For overall mortality
nd the rate of death from cardiovascular causes, reinfarction,
r hospitalization for HF, valsartan was as effective as captopril.
here was no added benefit for combining the drugs.
The goals of this analysis were to assess the effect of
aptopril, valsartan, or captopril plus valsartan on multiple
utcomes as a function of race. The specific outcomes of
nterest include: all-cause mortality, cardiovascular mortal-
ty, HF hospitalizations, recurrent MI, stroke, adverse
vents, and medication discontinuation.
ethods
tudy design. The methods for this trial have been previ-
usly described, and the main results were reported (12,15).
riefly, this was a randomized, double-blind trial conducted
n 24 countries. The entire trial included 14,703 patients.
he primary outcome was death from any cause. Valsartan
as compared with captopril and valsartan plus captopril for
he primary end point of overall mortality and the secondary
ardiovascular end points. If valsartan was not superior or
nferior to captopril, a noninferiority analysis (using both
ntention-to-treat and per-protocol analyses) was planned to
est the null hypothesis that valsartan and captopril were
omparable for the primary end point. There was no difference
n total mortality or the combined cardiovascular end point for
alsartan compared with captopril or valsartan plus captopril
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ARB  angiotensin
receptor blocker
CABG  coronary artery
bypass grafting
CHD  coronary heart
disease
eGFR  estimated
glomerular filtration rate
HF  heart failure
LVSD  left ventricular
systolic dysfunction
MI  myocardial infarction
PCI  percutaneous
coronary interventionersus captopril. Thus, valsartan was as effective as captopril ond combination therapy offered no added benefits, but did
ncrease the rate of adverse events.
This subset analysis includes 3,730 patients (3,390 white
nd 340 African-American patients) enrolled in the U.S.
en and women 18 years of age who sustained an acute
I complicated by clinical or radiographic signs of HF
nd/or evidence of LVSD by echocardiography, contrast
ngiography, or radionuclide ventriculography were en-
olled. Exclusion criteria included: systolic blood pressure
100 mm Hg, serum creatinine 2.5 mg/dl, previous
ntolerance or contraindication to ACE inhibitors or ARBs,
ignificant valvular heart disease, or a concomitant disease
everely limiting life expectancy. All patients were required
o provide written informed consent. The VALIANT study
sed 4 race/ethnicity categorizations that were obtained at
nrollment: white/Caucasian, black/African American, Asian,
nd other/unknown. Race was self-reported, and only pa-
ients identified as African American or white were included in
his analysis.
Consenting eligible patients were randomly assigned
:1:1 to treatment with valsartan, captopril, or a combina-
ion of captopril plus valsartan. The starting doses were
alsartan 20 mg, captopril 6.25 mg, or valsartan 20 mg plus
aptopril 6.25 mg once daily. The dose could be titrated up
o valsartan 160 mg twice daily, captopril 50 mg 3 times
aily, or valsartan 80 mg twice daily plus captopril 50 mg 3
imes daily. The doses used in each group could be titrated
ccording to the patient’s clinical status. A clinical end
oint committee blinded to treatment assignment adju-
icated primary end points. A single independent data
nd safety monitoring board and the institutional review
oard or ethics committee at each participating site
pproved the protocol.
tatistical analysis. All statistical analyses were performed
t the Duke Clinical Research Institute. African-American
atients were compared with white American patients on
-year clinical outcomes of all-cause mortality, cardiovascu-
ar mortality, hospitalization for HF, recurrent MI, and
troke. The null hypothesis was that there is no difference
etween African-American and white patients on a given
-year clinical outcome.
Comparison of baseline characteristics and adverse events
etween African Americans and white Americans were
arried out using a Pearson chi-square or Cochran-Mantel-
aenszel chi-square test, and a Wilcoxon rank sum test for
ategorical and continuous data, respectively. Clinical out-
omes at 3 years were analyzed using Cox regression models
tratified by race. Cumulative event rates through 3 years
ere estimated for both African Americans and white
mericans, after adjustment for baseline characteristics.
tepwise selection was used to choose baseline characteris-
ics and create a parsimonious model for each clinical
utcome. A p value of 0.10 was required for a variable to
nter and stay in the final model. Longitudinal analysis was
arried out to examine the effects of covariates to variables
f interest over time. Trajectories were plotted for visual
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May 13, 2008:1865–71 Racial Analysis of Patients With MI, HF, and/or LVSDxamination. We checked the assumption of normality as
ell as the possibility of including additional polynomial
erms in the model. A final linear mixed model was used to
nalyze these repeated measures over time.
The list of control variables for each clinical outcome is
eported in the Online Appendix. Standard errors of ad-
usted event rates were estimated by bootstrapping from the
riginal data with 500 resamples of the entire cases of data.
ifferential treatment effects on African Americans versus
hite Americans were tested by interactions between race
nd treatments adjusting for baseline characteristics.
Continuous variables were summarized as medians with
5th and 75th percentiles, and categorical variables as frequen-
ies and percentages. For a single comparison, a p value of 0.05
as considered statistically significant evidence to reject a null
ypothesis. For multiple comparisons, the significance level
as adjusted by the Bonferroni method.
The SAS software package (version 8, SAS Institute Inc.,
ary, North Carolina) was used for data analysis; SAS
ackboot macro (SAS Institute, Inc.) was used for boot-
trapping standard errors.
esults
aseline characteristics. Mean baseline total creatine
hosphokinase and troponin I were not significantly differ-
nt between African-American and white patients. African
mericans were younger, more often female, and also more
ikely than white Americans to have a history of diabetes
ellitus, chronic HF, and hypertension (Table 1). More-
ver, African Americans had a lower estimated glomerular
ltration rate (eGFR), higher systolic and diastolic blood
ressures, faster heart rate, and higher Killip class. Con-
ersely, white patients were more likely to have been
reviously hospitalized, to have undergone prior percutane-
us coronary intervention (PCI), and to have a history of
nstable angina. During the index hospitalization, HF and
enal insufficiency were observed in more African Ameri-
ans than white Americans.
African-American patients (84.1%) were as likely as
hite patients (88.6%) to undergo coronary angiography
fter acute MI. Among African Americans, the percentage
f the number of diseased coronary vessels was 5.9% (none),
0.4% (single), 24.5% (double), and 39.2% (triple). The
ercentage among white Americans was 1.7% (none),
0.8% (single), 27.2% (double), and 40.3% (triple). How-
ver, after adjusting for the presence of single-vessel,
ouble-vessel, and triple-vessel disease, African Americans
ere less likely than white Americans to receive PCI (p 
.003) or coronary artery bypass grafting (CABG) (p 
.021).
African Americans were more likely to be treated with an
CE inhibitor, long-acting nitrates, insulin, and non–
otassium-sparing diuretics (Table 2). White Americans
ere more likely to be treated with antiplatelet therapiesother than aspirin) and oral anticoagulants. At 1 year of vollow-up, comparisons by race of concomitant pharmaco-
herapies showed significant differences in several evidence-
ased medications. African Americans were more often
reated with beta-blockers, calcium-channel blockers, non–
otassium-sparing diuretics, long-acting nitrates, and other
asodilators. White Americans were more likely to be
reated with aspirin, statins, or other lipid modulating
herapies (Table 2).
utcomes. There were no significant differences in the
djusted 3-year rates of all-cause mortality (22.1% for
frican Americans vs. 20.3% for white Americans; p 
.45) or cardiovascular mortality (18.4% for African Amer-
cans vs. 16.7% for white Americans; p  0.31) (Fig. 1).
he recurrent MI rate at 3 years was similar between
frican Americans and white Americans. There was a trend
oward higher rates of HF hospitalizations for African-
merican patients compared with white Americans at 3
ears (p 0.09). The stroke rate for African Americans was
pproximately twice as high as for white Americans (8.0%
aseline Characteristics
Table 1 Baseline Characteristics
Characteristic
White American
(n  3,390)
African American
(n  340) p Value
Age, mean  SD, yrs 64.1 12.5 61.6 12.0 0.001
Age 65 yrs, % 49 40 0.002
Female, % 30 39 0.001
Weight, mean  SD, kg 86 19 87 22 0.391
BMI, mean  SD, kg/m2 29 6 30 7 0.087
eGFR, mean  SD,
ml/min/1.73 m2
89 40 84 39 0.047
Blood pressure, mean  SD,
mm Hg
Systolic 120 16 126 19 0.001
Diastolic 68 11 72 13 0.001
Heart rate, mean  SD,
beats/min
78 14 80 14 0.016
Prior diabetes, % 28 39 0.001
New diabetes, % 4 0.627
Smoker, % 31 36 0.064
X-ray HF, % 38 40 0.515
LBBB, % 5 2 0.068
Killip class, % 0.016
I 45 38
II 38 47
III 10 10
IV 7 6
Medical history, %
Unstable angina 18 14 0.067
Angina 30 24 0.027
MI 29 30 0.829
HF 15 24 0.001
Stroke 6 9 0.063
PVD 10 12 0.340
Cancer 4 3 0.198
Hypertension 55 79 0.001
MI  body mass index; eGFR  estimated glomerular filtration rate; HF  heart failure; LBBB 
eft bundle branch block; MI  myocardial infarction; PVD  peripheral vascular disease.s. 3.7%; p  0.06). The outcomes by race for all-cause
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Racial Analysis of Patients With MI, HF, and/or LVSD May 13, 2008:1865–71ortality, cardiovascular mortality, hospitalizations for HF,
ecurrent MI, and stroke were independent of treatment
ssignment (p 0.101 for tests of interactions between race
nd treatment assignment across different outcomes).
omparative treatment effect in African Americans. Af-
ican Americans treated with valsartan compared with
frican Americans treated with captopril alone or captopril
lus valsartan had similar cumulative all-cause mortality
ates (Fig. 2). Similarly, for the outcomes of cardiovascular
ortality, hospitalization for HF, recurrent MI, and stroke,
here were no differences among African-American patients
reated with any of the 3 medical regimens.
dverse events and medication discontinuation. White
atients were more likely than African Americans to expe-
ience hypotension (32.8% vs. 20.9%; p  0.0001). There
ere no racial differences in the incidence of dry cough,
hich occurred in approximately 19% of all patients (20.2%
or white patients vs. 18.8% for African Americans; p 
oncomitant Medicationsefore Randomization a d at 1 Year
Table 2 Concomitant MedicationsBefore Randomization and at 1 Year
Concomitant
Medications, % White American African American p Value
Prior to randomization (n  3,389) (n  340)
ACE inhibitor 44 52 0.011
ARB 2 2 0.586
Beta-blocker 78 79 0.529
Calcium-channel blocker 10 12 0.185
Potassium-sparing diuretic 6 9 0.028
Other diuretic 43 48 0.110
Digoxin 22 22 0.696
Amiodarone 5 7 0.423
Other antiarrhythmic 3 2 0.461
Long-acting nitrate 36 49 0.001
Other vasodilator 1 3 0.069
IV inotrope or IV vasopressor 3 1 0.072
Aspirin 92 93 0.803
GP IIb/IIIa inhibitor 17 18 0.674
Other antiplatelet 56 40 0.001
Heparin 37 44 0.023
Oral anticoagulant 16 11 0.012
Statin 49 47 0.199
Insulin 18 32 0.001
Oral hypoglycemic agent 15 13 0.244
Use at 1 year (n  2,757) (n  246)
Beta-blocker 76 82 0.034
Calcium-channel blocker 11 23 0.001
Potassium-sparing diuretic 9 13 0.050
Other diuretic 42 59 0.001
Digoxin 22 26 0.195
Amiodarone 5 5 0.748
Other antiarrhythmic 1 3 0.009
Nitrate excluding prophylaxis 21 33 0.001
Other vasodilator 1 2 0.136
IV inotrope or IV vasopressor 0.3 1 0.055
CE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; GP  glycoprotein;
V  intravenous..6), most of which was treated with captopril. Angioedemaas rare; however, among patients treated with captopril,
frican Americans were almost 2 times more likely than
hite patients to develop angioedema, a result that was not
tatistically significant (1.2% for white patients vs. 2.1% for
frican Americans; p  0.2). Adverse events led to discon-
inuation of treatment in 11% of the population treated.
ngioedema was the most common reason for discontinu-
ng captopril among African-American patients. Dry cough
as the most prevalent adverse event that led to medication
iscontinuation in white Americans.
There was a nonstatistically significant trend for the
evelopment of renal dysfunction in African-American
atients for all treatments compared with white patients
12.4% for white patients vs. 15.9% for African Americans;
 0.07). A longitudinal analysis showed that diuretic use
ver time and baseline renal insufficiency were strongly
Figure 1 Adjusted 3-Year Rates of CV Events by Race
The adjusted cardiovascular event rates are not significantly different between
African Americans and white patients. CHF  congestive heart failure;
CI  confidence interval; CV  cardiovascular; MI  myocardial infarction.
Figure 2 Cumulative All-Cause Mortality Rate of African
Americans on Different Randomized Treatments
There was no difference in all-cause mortality according to assigned therapy.
a
0
i
c
i
c
5
o
0
h
(
t
v
c
b
w
d
t
i
(
r
D
I
M
s
A
b
f
A
p
m
d
a
a
B
h
w
w
c
p
p
P
i
a
t
A
t
o
c
p
(
H
s
A
m
P
e
t
n
t
A
H
w
t
A
h
w
y
f
t
h
T
c
e
l
p
R
*
d
a
1869JACC Vol. 51, No. 19, 2008 Prisant et al.
May 13, 2008:1865–71 Racial Analysis of Patients With MI, HF, and/or LVSDssociated with renal dysfunction during the trial (p 
.0001 for both factors). In addition to having more renal
nsufficiency at baseline, African Americans had a signifi-
antly higher number of individuals who developed renal
nsufficiency from the post-qualifying MI to randomization
ompared with white patients; the absolute difference was
.58%. Furthermore, there were a significantly greater number
f African Americans taking diuretics overall as well (p 
.001). African Americans have significantly (p  0.0001)
igher rates of diuretic use before discontinuation of study drug
63.3%) compared with white patients (47.2%).
African Americans were more likely than white patients
o develop renal dysfunction and hyperkalemia requiring
alsartan discontinuation (Table 3). After adjusting for
hronic renal insufficiency (eGFR 60 ml/min/1.73 m2) at
aseline, the difference between African Americans and
hite American patients on developing renal dysfunction
uring the study was not significant (p 0.1346). However,
he difference between African Americans and white Amer-
cans on discontinuing valsartan treatment for renal causes
Table 3) persisted (p  0.0001) after adjusting for baseline
enal insufficiency.
iscussion
n a high-risk population with HF or LVSD after an acute
I, African-American patients treated with captopril, val-
artan, or both had similar clinical outcomes to white
merican patients, after adjusting for differences in comor-
idities. Despite having significantly more coronary risk
actors and more markers of poor outcome post-infarction,
frican Americans were less likely to be revascularized
ercutaneously or surgically after MI. This disparity re-
ained after adjusting for the extent of coronary artery
isease. The differential use of revascularization procedures
ccording to race has been extensively reported and is
ssociated with worse outcomes in several studies (16–19).
ecause there was a trend toward higher rates of HF
ospitalizations for African Americans compared with
hite Americans at 3 years, we can only speculate as to
easons Leading to Discontinuation by Treatment and Race
Table 3 Reasons Leading to Discontinuation by Treatment and
Adverse Event, %*
Captopril (n  1,246)
WA
(n  1,127)
AA
(n  119)
Hypotension† 0.5 0
Renal causes 0.6 0.8
Hyperkalemia 0.2 0
Cough 2.8 1.7
Skin rash 0.4 0
Taste disturbance 0.6 0
Angioedema 0.1‡ 2.5
Any adverse events 9.7 5.1
Includes patients who actually received any study medication. †Symptomatic hypotension is defin
izziness, faintness, diaphoresis) or persistent hypotension leading to dose reduction, temporary int
nd white patients was significant at p  0.05.
AA  African American; WA  white American.hether this is attributable to treatment with calcium-
hannel blockers, more coronary risk factors and poor
ost-infarction outcome markers, or fewer revascularization
rocedures.
rior studies. Conflicting results from several clinical trials
nvolving pharmacological blockade of the renin-angiotensin-
ldosterone system have led to questions about the efficacy of
hese agents in African Americans. In the AASK (African
merican Study of Kidney Disease and Hypertension), pa-
ients treated with the ACE inhibitor ramipril as the first drug
f combination therapy, as compared with a beta-blocker or
alcium antagonist as initial therapy, had a decrease in the
rogression of their renal disease (20,21). The ALLHAT
Antihypertensive and Lipid-Lowering Treatment to Prevent
eart Attack Trial) reported African Americans had more
trokes, more HF, and less blood pressure reduction on an
CE inhibitor compared with a diuretic, but not a higher total
ortality (13). In the LIFE (Losartan Intervention For End
oint Reduction in Hypertension) study, losartan was less
ffective than atenolol as a component of antihypertensive
herapy among African Americans in reducing fatal and
onfatal strokes (22). Retrospective analyses of 2 heart failure
rials concluded that ACE inhibitors were less effective in
frican Americans (14,23). In the V-HeFT (Vasodilator-
eart Failure Trial) II study, enalapril decreased mortality in
hite patients, but not in African-American patients (14). In
he SOLVD (Studies Of Left Ventricular Dysfunction) study,
frican-American patients had a poorer prognosis and did not
ave a reduction in total mortality or hospitalization for HF
ith enalapril compared with placebo (23). Subsequent reanal-
sis of the SOLVD dataset that adjusted for ventricular
unction was able to show only a weak nonsignificant trend
oward excess mortality, and a persistent trend in increased
ospitalizations for HF among African-American patients (4).
here have been a number of trials with ACE inhibitors
onducted in the post-infarction setting (6–10,24–26). How-
ver, only 1 trial, the SAVE (Survival And Ventricular En-
argement) study, included at least 125 African-American
atients (27). Unfortunately, the number of African-American
Valsartan (n  1,243) Valsartan  Captopril (n  1,218)
A
1,143)
AA
(n  100)
WA
(n  1,101)
AA
(n  117)
.8 0 2.4 1.7
.8‡ 6.0 1.4 0.9
.1‡ 2.0 0.2 0.9
.4 0 2.5 1.7
.7 0 1.0 0
.4 1.0 0.3 0
.3 0 0.4 0
.7 11.0 10.1 9.4
of the following: hypotension (including first-dose hypotension) accompanied by symptoms (e.g.,
n, or permanent discontinuation of study medication. ‡The difference between African AmericansRace
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Racial Analysis of Patients With MI, HF, and/or LVSD May 13, 2008:1865–71articipants did not permit an analysis of risk reduction for
otal mortality or cardiovascular morbidity and mortality (28).
African Americans compose approximately 10% of the
.S. VALIANT study population, which is consistent with
r larger than most clinical trials examining treatment
utcomes by race. Excluding the AASK study, the A-HeFT
African American Heart Failure) trial (21,29), (both of
hich enrolled only African Americans), the ALLHAT
tudy (13), and the BEST (Beta-Blocker Evaluation of
urvival Trial) (30), very few large clinical trials have
rospectively included enough African-American patients
o conclude meaningful observations. The landmark HOPE
Heart Outcomes Prevention Evaluation) trial (31) included
o few African-American patients that no definitive recom-
endations could be made regarding the efficacy of ramipril
n African-American patients at risk for cardiovascular events
32). A retrospective analysis of the LIFE trial that included
nly 6% African Americans reported a lack of benefit in this
ubgroup for losartan compared with atenolol in the primary
omposite end point (cardiovascular death, stroke, and MI)
22). This observation ultimately led to a product label stating
he benefits of losartan may not apply to African Americans
32). The data on the efficacy of ACE inhibitors in African-
merican patients with HF are largely derived from retrospec-
ive analyses of the SOLVD study, in which 12% of the
opulation was African American (4,5,23).
dverse events. Clinical studies indicate that the reduction
n blood pressure for African-American patients compared
ith white patients is less with a beta-blocker, an ACE
nhibitor, or an ARB when used as monotherapy (33–37).
onsistent with those studies, African Americans had a
iminished blood pressure response to ACE inhibitors and
RBs compared with white Americans, and consequently
ad a lower rate of clinically significant hypotension. Con-
ordant with prior reports, the rate of angioedema was
reater among African-American study participants com-
ared with white American participants (13,38). In the
LLHAT study, angioedema occurred in 0.7% of African-
merican patients assigned to lisinopril versus 0.3% of
on-African Americans. In our analysis of the U.S. portion
f the VALIANT study, angioedema by race was signifi-
antly different for patients treated with captopril, but did
ot reach statistical significance by race across all 3 treat-
ents. The VALIANT study excluded previous intolerance
r contraindication to an ACE inhibitor, and the number of
frican-American patients was relatively small.
tudy limitations. The VALIANT study was not specifi-
ally designed to explore outcomes according to race, and
esults are limited by the sample size. Although the number
f African Americans participating is relatively small, this
eport seems to be the largest cohort for an individual HF
ost-infarction trial treating patients with either an ACE
nhibitor or an ARB. The African-American and white
merican patients compared in this analysis differed at
aseline in several demographic and clinical factors. Statis-
ical modeling adjusted for many factors, yet there is theossibility of unaccounted factors that may affect the results
eported in this study. The use of hydralazine and isosorbide
initrate has been shown to decrease mortality in African-
merican patients with chronic moderate-to-severe HF.
he use of these medications was low in this study (4%);
owever, the VALIANT trial is a post-MI study and the
enefits of hydralazine and isosorbide dinitrate may not be
eneralizable to this population.
onclusions
n this analysis of U.S. participants in the VALIANT study,
here were no racial differences among post-MI patients
ith HF and/or LVSD treated with captopril, valsartan, or
he combination in the 3-year rates of all-cause mortality,
ardiovascular mortality, and recurrent MI. Hospitalization
ates for HF and stroke were higher for African-American
atients compared with white patients, although the p
alues for comparison were nonsignificant. A larger sample
ize may have yielded significant results. White patients
xperienced more hypotension than African Americans, and
frican Americans experienced more angioneurotic edema
han white patients treated with an ACE inhibitor. African-
merican patients with acute MI complicated by HF and/or
VSD are as likely to benefit from treatment with ACE
nhibitors or ARBs as white patients. It remains important to
rospectively include minority populations in clinical trials to
nsure that the potential benefits and adverse events of medi-
ations, devices, and other interventions are generalizable to all
atients.
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